Purpose Pharma Announces Positive CHMP Opinion for Attrogy®

Our portfolio company, Purpose Pharma, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Attrogy® (diflunisal). Attrogy® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

If approved by the European Commission (EC), Attrogy® will become the only oral therapy authorized for treating both stage 1 and stage 2 ATTR polyneuropathy.
This represents a major advancement for hATTR patients, offering a convenient and accessible oral treatment option that addresses a significant unmet need. Attrogy® could enable earlier and more sustained management of disease progression, helping patients maintain their quality of life longer.

About Purpose Pharma
Purpose Pharma is a biopharmaceutical company focused on developing innovative treatments for rare diseases with high unmet medical needs